Contineum Therapeutics Inc
CTNM12.228USD
-0.032-0.26%
Market hours （ET）Quotes delayed by 15 min
356.84MMarket Cap
LossP/E TTM
More Details of Contineum Therapeutics Inc Company
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Contineum Therapeutics Inc Info
Ticker SymbolCTNM
Company nameContineum Therapeutics Inc
IPO dateApr 05, 2024
CEOStengone (Carmine)
Number of employees41
Security typeOrdinary Share
Fiscal year-endApr 05
Address3565 General Atomics Court, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18583335280
Websitehttps://www.contineum-tx.com/
Ticker SymbolCTNM
IPO dateApr 05, 2024
CEOStengone (Carmine)
Company Executives of Contineum Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Mr. John Healy
Mr. John Healy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Daniel S. Lorrain, Ph.D.
Dr. Daniel S. Lorrain, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
6.97%
Johnson & Johnson Innovation-JJDC, Inc.
6.50%
Suvretta Capital Management, LLC
5.65%
Franklin Advisers, Inc.
5.44%
The Vanguard Group, Inc.
3.17%
Other
72.28%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
6.97%
Johnson & Johnson Innovation-JJDC, Inc.
6.50%
Suvretta Capital Management, LLC
5.65%
Franklin Advisers, Inc.
5.44%
The Vanguard Group, Inc.
3.17%
Other
72.28%
Shareholder Types
Shareholders
Proportion
Venture Capital
17.13%
Hedge Fund
14.65%
Investment Advisor/Hedge Fund
12.53%
Investment Advisor
10.93%
Private Equity
2.35%
Individual Investor
1.14%
Sovereign Wealth Fund
0.56%
Research Firm
0.22%
Other
40.50%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
157
17.77M
74.57%
+5.77K
2025Q3
157
17.77M
75.64%
+1.66M
2025Q2
138
13.97M
83.77%
-1.34M
2025Q1
111
15.31M
83.95%
-757.12K
2024Q4
103
15.81M
72.85%
+2.07M
2024Q3
87
13.74M
68.70%
+690.91K
2024Q2
69
13.04M
62.55%
+1.16M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
2.12M
9.81%
+2.12M
--
Jul 25, 2025
Johnson & Johnson Innovation-JJDC, Inc.
1.98M
9.15%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
1.72M
7.95%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
1.70M
7.86%
+122.64K
+7.78%
Jun 30, 2025
The Vanguard Group, Inc.
744.00K
3.44%
-59.43K
-7.40%
Jun 30, 2025
Fidelity Management & Research Company LLC
843.15K
3.9%
+32.83K
+4.05%
Jun 30, 2025
Sectoral Asset Management Inc.
800.79K
3.7%
--
--
Jun 30, 2025
Perceptive Advisors LLC
699.49K
3.23%
-741.76K
-51.47%
Jun 30, 2025
HHLR Advisors, Ltd.
669.34K
3.1%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
Schwab U.S. Small-Cap ETF
0%
Janus Henderson Small Cap Growth Alpha ETF
0%
iShares Russell 2000 Growth ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Contineum Therapeutics Inc?
The top five shareholders of Contineum Therapeutics Inc are:
RA Capital Management, LP holds 2.12M shares, accounting for 9.81% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 1.98M shares, accounting for 9.15% of the total shares.
Suvretta Capital Management, LLC holds 1.72M shares, accounting for 7.95% of the total shares.
Franklin Advisers, Inc. holds 1.70M shares, accounting for 7.86% of the total shares.
The Vanguard Group, Inc. holds 744.00K shares, accounting for 3.44% of the total shares.
RA Capital Management, LP holds 2.12M shares, accounting for 9.81% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 1.98M shares, accounting for 9.15% of the total shares.
Suvretta Capital Management, LLC holds 1.72M shares, accounting for 7.95% of the total shares.
Franklin Advisers, Inc. holds 1.70M shares, accounting for 7.86% of the total shares.
The Vanguard Group, Inc. holds 744.00K shares, accounting for 3.44% of the total shares.
What are the top three shareholder types of Contineum Therapeutics Inc?
The top three shareholder types of Contineum Therapeutics Inc are:
RA Capital Management, LP
Johnson & Johnson Innovation-JJDC, Inc.
Suvretta Capital Management, LLC
RA Capital Management, LP
Johnson & Johnson Innovation-JJDC, Inc.
Suvretta Capital Management, LLC
How many institutions hold shares of Contineum Therapeutics Inc (CTNM)?
As of 2025Q4, 157 institutions hold shares of Contineum Therapeutics Inc, with a combined market value of approximately 17.77M, accounting for 74.57% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.07%.
What is the biggest source of revenue for Contineum Therapeutics Inc?
In --, the -- business generated the highest revenue for Contineum Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
